WHO Diagnostic Criteria for Systemic Mastocytosis (2016)

ورودی‌های بالینی بیمار

حداقل ۰ — حداکثر ۲۰۰ • واحد: ng/mL

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
diagnosis status
—categorical
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

Direct Clinical Answer

The WHO Diagnostic Criteria for Systemic Mastocytosis (2016) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include multifocal mast cell infiltrates. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

World Health Organization 2016 diagnostic criteria for systemic mastocytosis. Requires 1 major criterion + 1 minor criterion OR 3 minor criteria for diagnosis. Used to distinguish systemic mastocytosis from cutaneous mastocytosis and other mast cell disorders.

Clinical Indication

The WHO Diagnostic Criteria for Systemic Mastocytosis (2016) is indicated for bedside clinical practice to support World Health Organization 2016 diagnostic criteria for systemic mastocytosis. Requires 1 major criterion + 1 minor criterion OR 3 minor criteria for diagnosis. Used to distinguish systemic mastocytosis from cutaneous mastocytosis and other mast cell disorders.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.

Formula & Variables:

Diagnosis requires: (1 major criterion + 1 minor criterion) OR (3 minor criteria). Major criterion: multifocal mast cell infiltrates ≥15 cells. Minor criteria: (1) atypical morphology ≥25%, (2) KIT mutations, (3) aberrant CD expression, (4) serum tryptase >20 ng/mL.

Input Parameters

NameTypeRequiredDescription
multifocal_mast_cell_infiltratesstringYesMultifocal dense infiltrates of mast cells (≥15 mast cells in aggregates) in bone marrow biopsies and/or other extracutaneous organ sections
atypical_mast_cell_morphologystringYes≥25% of mast cells are atypical (type I or II) on bone marrow smears or spindle-shaped in mast cell infiltrates
kit_mutationstringYesKIT-activating point mutations at codon 816 (usually D816V) or other critical KIT regions
aberrant_cd_expressionstringYesMast cells express CD2 and/or CD25 and/or CD30 (in addition to normal mast cell markers) by flow cytometry or immunohistochemistry
serum_tryptasefloatYesBaseline serum tryptase concentration in ng/mL (normal <11.4 ng/mL, criterion met if >20 ng/mL in absence of associated myeloid neoplasm)(ng/mL)
associated_myeloid_neoplasmstringYesPresence of associated myeloid neoplasm (affects interpretation of serum tryptase criterion)

Evidence-Based References (EBM)

  • Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere. 2021;5(11):e646. doi: 10.1097/HS9.0000000000000646DOI: 10.1097/HS9.0000000000000646
  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. doi: 10.1182/blood-2016-03-643544DOI: 10.1182/blood-2016-03-643544
  • Valent P, Alin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420-1427. doi: 10.1182/blood-2016-09-731893DOI: 10.1182/blood-2016-09-731893
  • Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol. 2023;98(8):1306-1325. doi: 10.1002/ajh.26962DOI: 10.1002/ajh.26962

Related calculators